{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:50:34Z","timestamp":1789732234643,"version":"4.0.1"},"reference-count":44,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T00:00:00Z","timestamp":1676764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background: Postmenopausal osteoporosis is a multifactorial disease. Genetic factors play an essential role in contributing to bone mineral density (BMD) variability, which ranges from 60 to 85%. Alendronate is used as the first line of pharmacological treatment for osteoporosis; however, some patients do not respond adequately to therapy with alendronate. Aim: The aim of this work was to investigate the influence of combinations of potential risk alleles (genetic profiles) associated with response to anti-osteoporotic treatment in postmenopausal women with primary osteoporosis. Methods: A total of 82 postmenopausal women with primary osteoporosis receiving alendronate (70 mg administered orally per week) for one year were observed. The bone mineral density (BMD; g\/cm2) of the femoral neck and lumbar spine was measured. According to BMD change, patients were divided into two groups: responders and non-responders to alendronate therapy. Polymorphic variants in CYP19, ESR1, IL-6, PTHR1, TGF\u03b2, OPG and RANKL genes were determined and profiles were generated from the combination of risk alleles. Results: A total of 56 subjects were responders to alendronate and 26 subjects were non-responders. Carriers of the G-C-G-C profile (constructed from rs700518, rs1800795, rs2073618 and rs3102735) were predisposed to response to alendronate treatment (p = 0.001). Conclusions: Our findings highlight the importance of the identified profiles for the pharmacogenetics of alendronate therapy in osteoporosis.<\/jats:p>","DOI":"10.3390\/genes14020524","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T04:58:23Z","timestamp":1676869103000},"page":"524","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8261-7893","authenticated-orcid":false,"given":"Alejandra","family":"Villag\u00f3mez Vega","sequence":"first","affiliation":[{"name":"Doctorado en Farmacolog\u00eda, Departamento de Fisiolog\u00eda, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44280, Mexico"},{"name":"Centro de Investigaci\u00f3n Multidisciplinario en Salud, Departamento de Ciencias Biom\u00e9dicas, Centro Universitario de Tonal\u00e1, Universidad de Guadalajara, Guadalajara 45425, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Iv\u00e1n","family":"G\u00e1mez Nava","sequence":"additional","affiliation":[{"name":"Doctorado en Farmacolog\u00eda, Departamento de Fisiolog\u00eda, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44280, Mexico"},{"name":"Doctorado en Salud P\u00fablica, Departamento de Salud P\u00fablica, Centro Universitario de Ciencias de la Salud, Guadalajara 44280, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Ruiz Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Cl\u00ednica de Osteoporosis del Antiguo Hospital Civil \u201cFray Antonio Alcalde\u201d, Divisi\u00f3n de Medicina Interna, Guadalajara 44280, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misael","family":"P\u00e9rez Romero","sequence":"additional","affiliation":[{"name":"Cl\u00ednica de Osteoporosis del Antiguo Hospital Civil \u201cFray Antonio Alcalde\u201d, Divisi\u00f3n de Medicina Interna, Guadalajara 44280, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter \u00c1ngel","family":"Trujillo Rangel","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Multidisciplinario en Salud, Departamento de Ciencias Biom\u00e9dicas, Centro Universitario de Tonal\u00e1, Universidad de Guadalajara, Guadalajara 45425, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0386-1004","authenticated-orcid":false,"given":"Ismael","family":"Nu\u00f1o Arana","sequence":"additional","affiliation":[{"name":"Doctorado en Farmacolog\u00eda, Departamento de Fisiolog\u00eda, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44280, Mexico"},{"name":"Centro de Investigaci\u00f3n Multidisciplinario en Salud, Departamento de Salud y Enfermedad, Centro Universitario de Tonal\u00e1, Universidad de Guadalajara, Guadalajara 45425, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/978-981-13-3681-2_16","article-title":"Osteoporosis and the Ageing Skeleton","volume":"91","author":"Aspray","year":"2019","journal-title":"Subcell. Biochem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/pme.10.55","article-title":"Genetics of osteoporosis: Perspectives for personalized medicine","volume":"7","author":"Li","year":"2010","journal-title":"Pers. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mondockova, V., Adamkovicova, M., Lukacova, M., Grosskopf, B., Babosova, R., Galbavy, D., Martiniakova, M., and Omelka, R. (2018). The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women. BMC Med. Genet., 19.","DOI":"10.1186\/s12881-018-0684-8"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41588-018-0302-x","article-title":"An atlas of genetic influences on osteoporosis in humans and mice","volume":"51","author":"Morris","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2217\/pgs.13.40","article-title":"The future of pharmacogenetics for osteoporosis","volume":"14","author":"Marini","year":"2013","journal-title":"Pharmacogenomics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bone.2008.08.120","article-title":"Gene expression profile of the bone microenvironment in human fragility fracture bone","volume":"44","author":"Hopwood","year":"2009","journal-title":"Bone"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1210\/jc.2007-0646","article-title":"The Role of Receptor Activator of Nuclear Factor-\u03baB (RANK)\/RANK Ligand\/Osteoprotegerin: Clinical Implications","volume":"92","author":"Vega","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jsbmb.2009.10.013","article-title":"Gene\u2013gene interactions in RANK\/RANKL\/OPG system influence bone mineral density in postmenopausal women","volume":"118","author":"Zupan","year":"2010","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4061\/2011\/230671","article-title":"Aromatase Activity and Bone Loss in Men","volume":"2011","author":"Merlotti","year":"2011","journal-title":"J. Osteoporos."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s00223-004-0163-4","article-title":"Transforming Growth Factor \u03b2-1 Gene Polymorphisms and Bone Turnover, Bone Mineral Density and Fracture Risk in Southern Chinese Women","volume":"74","author":"Lau","year":"2004","journal-title":"Calcif. Tissue Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3410\/B2-63","article-title":"Pharmacogenetics of osteoporosis","volume":"2","author":"Marini","year":"2010","journal-title":"F1000 Biol. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.trsl.2016.10.009","article-title":"Using GWAS to identify novel therapeutic targets for osteoporosis","volume":"181","author":"Sabik","year":"2017","journal-title":"Transl. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten Years\u2019 Experience with Alendronate for Osteoporosis in Postmenopausal Women","volume":"350","author":"Bone","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00198-014-2619-3","article-title":"Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis","volume":"25","author":"Cairoli","year":"2014","journal-title":"Osteoporos. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.clinthera.2008.03.008","article-title":"Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment","volume":"30","author":"Sebba","year":"2008","journal-title":"Clin. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00198-008-0659-2","article-title":"Inadequate responders to osteoporosis treatment: Proposal for an operational definition","volume":"19","year":"2008","journal-title":"Osteoporos. Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/jbmr.1496","article-title":"Risk factors for prediction of inadequate response to antiresorptives","volume":"27","author":"Olmos","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00774-018-0931-2","article-title":"Factors associated with inadequate responses to risedronate in Japanese patients with osteoporosis","volume":"37","author":"Okazaki","year":"2018","journal-title":"J. Bone Miner. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1285216","DOI":"10.1155\/2020\/1285216","article-title":"Association of Polymorphisms in RANK and RANKL Genes with Osteopenia in Arab Postmenopausal Women","volume":"2020","author":"Abdi","year":"2020","journal-title":"Dis. Markers"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/gme.0b013e3181c617e6","article-title":"Management of osteoporosis in Postmenopausal women","volume":"17","author":"Ettinger","year":"2010","journal-title":"Menopause"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00198-011-1555-8","article-title":"Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women","volume":"23","author":"Breuil","year":"2011","journal-title":"Osteoporos. Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","article-title":"Executive Summary of the 2013 International Society for Clinical Densitometry Position Development Conference on Bone Densitometry","volume":"16","author":"Schousboe","year":"2013","journal-title":"J. Clin. Densitom."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.fsigss.2009.08.152","article-title":"Successful STR and SNP typing of FTA Card samples with low amounts of DNA after DNA extraction using a Qiagen BioRobot\u00ae EZ1 Workstation","volume":"2","author":"Rockenbauer","year":"2009","journal-title":"Forensic Sci. Int. Genet. Suppl. Ser."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/2211068213484472","article-title":"Evaluation of Four Automated Protocols for Extraction of DNA from FTA Cards","volume":"18","author":"Stangegaard","year":"2013","journal-title":"SLAS Technol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1050-3862(98)00019-9","article-title":"Allelic discrimination using fluorogenic probes and the 5\u2032 nuclease assay","volume":"14","author":"Livak","year":"1999","journal-title":"Genet. Anal. Biomol. Eng."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"528","DOI":"10.7326\/0003-4819-151-8-200910200-00006","article-title":"Collaborative meta-analysis: Associations of 150 candidate genes with osteoporosis and osteoporotic fracture","volume":"151","author":"Richards","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_27","first-page":"376197","article-title":"Osteoprotegerin polymorphisms in a Mexican population with rheumatoid arthritis and generalized osteoporosis: A preliminary report","volume":"2015","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.arcmed.2008.05.006","article-title":"Association of Interleukin-6 Gene Polymorphisms with Bone Mineral Density in Mexican Women","volume":"39","author":"Cisneros","year":"2008","journal-title":"Arch. Med. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.gene.2013.07.008","article-title":"Impact of genetic variants of IL-6, IL6R, LRP5, ESR1 and SP7 genes on bone mineral density in postmenopausal Mexican-Mestizo women with obesity","volume":"528","author":"Coronel","year":"2013","journal-title":"Gene"},{"key":"ref_30","unstructured":"Nice.org.uk (2022, April 13). 1 Recommendations|Bisphosphonates for Treating Osteoporosis|Guidance|NICE. Available online: https:\/\/www.nice.org.uk\/guidance\/ta464\/chapter\/1-Recommendations."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0749-0690(02)00022-8","article-title":"Osteoporosis in elderly: Prevention and treatment","volume":"18","author":"Srivastava","year":"2002","journal-title":"Clin. Geriatr. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1258\/136218004774202409","article-title":"Non-response to osteoporosis treatment","volume":"10","author":"Francis","year":"2004","journal-title":"Br. Menopause Soc. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1359\/jbmr.090818","article-title":"Clinical Value of Monitoring BMD in Patients Treated with Bisphosphonates for Osteoporosis","volume":"24","author":"Watts","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrendo.2013.3","article-title":"Genetic profiling and individualized assessment of fracture risk","volume":"9","author":"Nguyen","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Marozik, P., Alekna, V., Rudenko, E., Tamulaitiene, M., Rudenka, A., Mastaviciute, A., Samokhovec, V., Cernovas, A., Kobets, K., and Mosse, I. (2019). Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0221511"},{"key":"ref_36","first-page":"7680434","article-title":"Polymorphism rs2073618 of the TNFRSF11B (OPG) Gene and Bone Mineral Density in Mexican Women with Rheumatoid Arthritis","volume":"2017","year":"2017","journal-title":"J. Immunol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Piedra, M., Garc\u00eda-Unzueta, M.T., Berja, A., Paule, B., A Lav\u00edn, B., Valero, C., A Riancho, J., and A Amado, J. (2011). Single nucleotide polymorphisms of the OPG\/RANKL system genes in primary hyperparathyroidism and their relationship with bone mineral density. BMC Med. Genet., 12.","DOI":"10.1186\/1471-2350-12-168"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bone.2013.04.021","article-title":"Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER (+) breast cancer","volume":"55","author":"Napoli","year":"2013","journal-title":"Bone"},{"key":"ref_39","first-page":"820","article-title":"Interleukin-6 promoter polymorphism is associated with bone quality assessed by calcaneus ultrasound and previous fractures in a cohort of 75-year-old women","volume":"15","author":"Gerdhem","year":"2004","journal-title":"Osteoporos. Int."},{"key":"ref_40","first-page":"212","article-title":"The association between interleukin 6 \u2212174 G\/C gene polymorphism and the risk of osteoporosis: A meta-analysis","volume":"12","author":"Fajar","year":"2017","journal-title":"J. Taibah Univ. Med. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1210\/jc.2007-1019","article-title":"Osteoprotegerin Lys3Asn Polymorphism and the Risk of Fracture in Older Women","volume":"93","author":"Moffett","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.bone.2009.01.256","article-title":"Allelic variations of RANK\/RANKL\/OPG signaling system is related to bone mineral density and in vivo gene expression","volume":"44","author":"Takacs","year":"2009","journal-title":"Bone"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1345\/aph.1P439","article-title":"Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis","volume":"45","author":"Karaplis","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/aje\/kwi055","article-title":"Estrogen Receptor Gene Polymorphisms and the Genetics of Osteoporosis: A HuGE Review","volume":"161","author":"Gennari","year":"2005","journal-title":"Am. J. Epidemiol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/2\/524\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:36:28Z","timestamp":1760121388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/2\/524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,19]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["genes14020524"],"URL":"https:\/\/doi.org\/10.3390\/genes14020524","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,19]]}}}